EPAM
EPAM Systems, Inc.
EPAM's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over EPAM overall, supported by stronger modeled upside and stronger fundamentals.
EPAM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
EPAM's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
EPAM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $164 | — |
| Current | 21x | $164 | — |
| Cheap | 24x | $188 | +15% |
| Fair | 36x | $291 | +78% |
| Expensive | 65x | $517 | +216% |
Historical ranges are pointers, not guarantees.
EPAM's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over EPAM in the historical PE scenario, which offers more potential upside but is not a forecast.
EPAM Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect EPAM's earnings to grow and its profitability to improve, with its revenue holding steady.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
EPAM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $14.10 | +76% |
| Q3 2026 | $7.99 | +22% |
| Q2 2026 | $7.37 | +5.1% |
| Q1 2026 | $6.96 | -2.7% |
| Q4 2025 | $6.72 | -14% |
| Q3 2025 | $6.55 | -15% |
| Q2 2025 | $7.01 | +0.6% |
| Q1 2025 | $7.15 | -2.1% |
| Q4 2024 | $7.84 | +11% |
EPAM earned $7.99 per share over the past year, up 22% from the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over EPAM on earnings, with more consistent year-over-year improvement.
EPAM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +2.3% |
| Q2 2026 | $1.4B | +4.5% |
| Q1 2026 | $1.4B | +7.6% |
| Q4 2025 | $1.4B | +13% |
| Q3 2025 | $1.4B | +19% |
| Q2 2025 | $1.4B | +18% |
| Q1 2025 | $1.3B | +12% |
| Q4 2024 | $1.2B | +7.9% |
EPAM's revenue has grown year over year for nine quarters in a row: $1.4B last quarter, up 2.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | +1.9 points |
| Q2 2026 | 11% | +1.4 points |
| Q1 2026 | 8.3% | +0.7 points |
| Q4 2025 | 11% | -0.3 points |
| Q3 2025 | 10% | -4.8 points |
| Q2 2025 | 9.3% | -1.2 points |
| Q1 2025 | 7.6% | -1.9 points |
| Q4 2024 | 11% | +0.4 points |
EPAM's operating margin was 12% last quarter, up 1.9 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over EPAM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over EPAM on profitability, with a higher operating margin.
EPAM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $274.2M | -4.3% |
| Q2 2026 | -$17.6M | -141% |
| Q1 2026 | -$54.2M | -466% |
| Q4 2025 | $268.1M | +134% |
| Q3 2025 | $286.4M | +21% |
| Q2 2025 | $43.4M | -17% |
| Q1 2025 | $14.8M | -88% |
| Q4 2024 | $114.5M | -29% |
EPAM generated $470M in free cash flow over the past year, up 2.5% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over EPAM on cash flow, with more consistent year-over-year improvement.
EPAM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -798K shares |
| 1 year | -7.8% | -4.3M shares |
| 3 years | -13% | -7.5M shares |
| 5 years | -13% | -7.7M shares |
| Available history | -11% | -6.2M shares |
EPAM has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $79.9M |
| Q2 2026 | $85M |
| Q1 2026 | $324M |
| Q4 2025 | $223.5M |
| Q3 2025 | $82.1M |
| Q2 2025 | $196.5M |
| Q1 2025 | $160M |
| Q4 2024 | $13M |
EPAM spent $712M buying back its own shares over the past year, up 58% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
EPAM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -2.0x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -1.8x | Net Cash |
| Q4 2024 | -2.0x | Net Cash |
EPAM has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
EPAM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.8 | Overbought |
| Stochastic | 93.9 | Overbought |
EPAM's weekly RSI is 72 (overbought) and its Stochastic is 94 (overbought).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
EPAM PE vs Technology Sector
| Metric | EPAM | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 26% below |
| PE % | 11 | 35 | 24 pts below |
EPAM has the edge over NVDA on valuation relative to its sector.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
EPAM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $131.5 | 25% above |
| 20 week MA | $114.0 | 44% above |
| 50 week MA | $134.5 | 22% above |
| 100 week MA | $158.5 | 3.3% above |
| 200 week MA | $203.6 | 20% below |
EPAM has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
EPAM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $214.4 | $356.3 | +66% |
| 2021 | $356.3 | $663.1 | +86% |
| 2022 | $663.1 | $323.7 | -51% |
| 2023 | $323.7 | $297.3 | -8.1% |
| 2024 | $297.3 | $238.5 | -20% |
| 2025 | $238.5 | $211.4 | -11% |
| 2026 YTD | $211.4 | $163.8 | -23% |
EPAM has finished four years in a row lower, and it's down 23% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over EPAM on returns for 2026, with the stronger performance.